SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume rally has sparked widespread short-squeeze speculation, with bullish traders focused on resistance levels and high short interest. No new catalyst is confirmed; traders also cite anticipated Anktiva label-expansion decisions and trial data, while skeptics question whether the advance can hold without concrete news.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showing slower upper-limb deterioration in Duchenne muscular dystrophy patients treated with deramiocel has sparked attention ahead of an FDA decision. Traders see the results as supportive, while others question whether the open-label data address the FDAs prior statistical concerns; short-squeeze chatter remains speculative.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is drawing attention amid a selloff in long-duration Treasuries as yields climb to multi-year highs; traders cite persistent inflation and rate-hike risks, alongside concerns about deficits and confidence in U.S. debt. Most discussion is bearish and questions why bonds are falling despite softer PCE data, while some traders see an oversold market and expect a rebound.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Fords persistent slide and test of support around the low-$12 range dominate discussion, with traders citing tariff and trade-policy uncertainty, high borrowing costs, and concerns about auto demand. Bulls are treating the weakness as a buying opportunity and looking for a seasonal rebound, while bears expect further downside.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys strong Q2 results and QNX automotive momentumhighlighted by a newly announced QNX-powered smart-camera program with a major German automakerare driving attention. Bulls view the results and design win as signs of growth, while others question whether the volatile rally can hold near resistance.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await the event-driven Phase 3 REGAL readout for galinpepimut-S (GPS), with discussion centered on whether the trial has reached its 80-death threshold. Bulls view the prolonged wait since the last reported event count as a possible sign of extended survival, while skeptics note the trial remains blinded and other factors could explain the delay; frustration with the companys quiet period is also common.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digitals steep pullback and upcoming fiscal Q1 earnings are dominating discussion, with traders looking for results, guidance or an RFS/lease update to provide a catalyst after a prolonged stretch of weak price action. Bulls are buying the dip and pointing to the companys AI data-center pipeline, while skeptics cite financing and dilution concerns, limited communication and uncertainty over execution.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas positive Phase 3 Hetlioz results for delayed sleep-wake phase disorder are the main focus, with the company planning to discuss the data with the FDA and seek an expanded indication. Traders are split: some see a meaningful pipeline opportunity, while others question the small trial and generic competition and are frustrated that the share price weakened despite the readout.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is drawing attention as its shares slide amid concerns that Kalshi and Polymarket are taking sports-wagering share and that prediction-market regulation remains uncertain. Traders are split: bears point to competition and investment costs, while bulls cite DKeXs growing trading volume as a potential growth driver.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagras latest results beat earnings expectations, but declining sales volume and an unchanged, cautious full-year outlook have weighed on the shares. Traders are split between viewing the selloff as excessive given the earnings beat and seeing weak demand and the lack of a guidance upgrade as reasons for continued caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prime Medicine Gets FDA Green Light for Gene Editing Study

The FDA clears Prime Medicine's IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.read more...

Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.read more...

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million.
Onconetix (NASDAQ:ONCO) stock roseread more...

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Equity

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.read more...

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics. 


Here's Why H.C. Wainwright Upgraded Prime Medicine (PRME) To "Buy"

Here's Why H.C. Wainwright Upgraded Prime Medicine (PRME) To "Buy...

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Inc

Extremely Bullish Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Micron ($MU) reports earnings after the close today. What do you expect?

Stocktwits

Micron Technology Inc

) reports earnings after the close today. What do you expect?

PRME Prime Medicine Inc